Press releases
- GSK begins shipping another record supply of influenza vaccine for 2021-22 season in US
- ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
- ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
Tweets from GSK US
-
GSKUS @GSKUS
Our own Michael Petroutsas, SVP, US Oncology Business Unit Head, joins @shannonmiller96 next week to discuss how we build upon lessons learned during the pandemic to improve #cancercare during a segment presented by GSK. #postlive
about 1 day ago -
GSKUS @GSKUS
Today, we’re proud to begin shipping 50M+ doses of our #flu vaccines to the US, another record for GSK, to help #FightFlu during the upcoming season! gsk.to/3iMiXF0
about 1 day ago -
GSKUS @GSKUS
“Science & research are a number of failures sprinkled w/ occasional success. Learning from both drives scientific discoveries.” Meet Manolis @dermitzakis, VP of Computational Biology, who recently received the Curt Stern Award from ASHG @GeneticsSociety. #genetics #innovation
about 2 days ago
